Why should PsiOxus win the Genesis BioNewsRound 2017 Award · Why should PsiOxus win the Genesis BioNewsRound 2017 Award ……? ... Proven intravenous delivery of an oncolytic virus

1

Why should PsiOxus win the Genesis

BioNewsRound 2017 Award ……?

November, 2017

• Announced December, 2016

• Worldwide exclusive licence of NG-348: asset specific, PsiOxus retains

T-SIGn platform rights

• $936 million up-front and milestones

• $50m up-front

• Royalties on net sales

• Pre-clinical development funding

• BMS responsible for clinical development and commercialization

• FTIH initiation expected in 2017

2

Because of the deal that we signed …

NG-348: First T-SIGn Collaboration

Proven intravenous delivery of an oncolytic virus

• Unique Ad11/Ad3 chimeric virus, created to survive in blood and target tumors

• Clinical data with Enadenotucirev “EnAd” virus shows IV delivery

• Targets most solid tumors (epithelial tumors)

• Clinical-only collaboration with Bristol-Myers Squibb:

• Enadenotucirev + Opdivo® in multiple tumor cohorts

Because that deal underpins our ambitions ….

PsiOxus Vision - to be the world-leading cancer gene therapy company

PsiOxus T-SIGn platform: Gene Therapy for Cancer

• Broad platform for gene therapy combinations

• Tumor microenvironment expression of a multitude of combinations and

pathways: bi-specifics, antibodies, cytokines, shRNA

• Single virus delivering combinations may have commercial advantages for

patients, physicians and payors

• Multiple preclinical gene therapy candidates plus ongoing generation of

new T-SIGn viruses3

Tumor Specific Immuno Gene Therapy: T-SIGn

Armed enadenotucirev, deliver IV immuno-therapeutic gene

therapy to local tumor sites

4

Local immunotherapy delivery to tumors

• Effective concentrations in local

microenvironments

• Minimized systemic exposure for

improved safety

Supporting clinical data with

Enadenotucirev

1. Dose and dosing regimen established for

systemic dosing.

2. Acceptable safety/tolerability profile:

• Primarily acute reactions to particles or

cytokines induced

• No clinical evidence of off-target virus

replication

3. Virus is selectively detected in tumor

cells and produces virus capsid protein.

4. Evidence of T-cell response in tumors.

Local activation of

anti-tumor immunity

T cell

APC

Tumor cells T-SIGn

Virus

Virus

genome

Immunogene

expression

Because that deal highlights our unique

technology ….

5

Clinical and pre-clinical stage products

Because that deal highlights the value and

potential of our pipeline ….

• UK built development stage immuno-oncology company• Borne out of Imperial, University of Birmingham with close ties to University of Oxford

• UK labs at Abingdon Science Park and Milton Park• ~ 65 staff majority in research labs

• Efficient outsourced model in manufacturing and development

• Now International• Opened Philadelphia, USA offices in 2017

• Financing• Raise £55M in VC funding Series A-C

• Raised more than this amount through non dilutive collaborations

6

Because that deal has enabled our ongoing

growth and value to our investors ….